CA2846644C - Method of reducing exercise-induced joint pain in non-arthritic mammals - Google Patents
Method of reducing exercise-induced joint pain in non-arthritic mammals Download PDFInfo
- Publication number
- CA2846644C CA2846644C CA2846644A CA2846644A CA2846644C CA 2846644 C CA2846644 C CA 2846644C CA 2846644 A CA2846644 A CA 2846644A CA 2846644 A CA2846644 A CA 2846644A CA 2846644 C CA2846644 C CA 2846644C
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- pain
- undenatured type
- knee
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 61
- 241000124008 Mammalia Species 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title abstract description 26
- 230000002917 arthritic effect Effects 0.000 title description 12
- 102000000503 Collagen Type II Human genes 0.000 claims abstract description 116
- 108010041390 Collagen Type II Proteins 0.000 claims abstract description 116
- 206010003246 arthritis Diseases 0.000 claims abstract description 42
- 210000000629 knee joint Anatomy 0.000 claims description 28
- 238000011084 recovery Methods 0.000 claims description 14
- 230000033001 locomotion Effects 0.000 claims description 10
- 239000013589 supplement Substances 0.000 claims description 10
- 208000024765 knee pain Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 3
- 230000009692 acute damage Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- -1 gummy chewable Substances 0.000 claims description 2
- 239000006194 liquid suspension Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 description 60
- 230000036407 pain Effects 0.000 description 59
- 210000003127 knee Anatomy 0.000 description 52
- 201000008482 osteoarthritis Diseases 0.000 description 37
- 229940068196 placebo Drugs 0.000 description 35
- 239000000902 placebo Substances 0.000 description 35
- 210000001612 chondrocyte Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 210000000845 cartilage Anatomy 0.000 description 15
- 102000003814 Interleukin-10 Human genes 0.000 description 12
- 108090000174 Interleukin-10 Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 241000219061 Rheum Species 0.000 description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 10
- 208000009386 Experimental Arthritis Diseases 0.000 description 9
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000008407 joint function Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000001925 catabolic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003349 osteoarthritic effect Effects 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010071155 Autoimmune arthritis Diseases 0.000 description 3
- 102000055008 Matrilin Proteins Human genes 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000037231 joint health Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 229960000371 rofecoxib Drugs 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000016284 Aggrecans Human genes 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 208000016593 Knee injury Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 101710170513 Retinoic acid receptor responder protein 2 Proteins 0.000 description 2
- 102100033914 Retinoic acid receptor responder protein 2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 108010003059 aggrecanase Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 229940127558 rescue medication Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 1
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000027502 Ankle fracture Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GAXKVISKILFMIE-UHFFFAOYSA-N C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(CCCCCCCC=C/CC=C/CC=C/CC)(=O)O Chemical compound C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(C=CCC)(=O)O.C(CCCCCCCC=C/CC=C/CC=C/CC)(=O)O GAXKVISKILFMIE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 241000272183 Geococcyx californianus Species 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000000876 binomial test Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895332P | 2013-10-24 | 2013-10-24 | |
| US61/895,332 | 2013-10-24 | ||
| PCT/US2014/011303 WO2015060888A1 (en) | 2013-10-24 | 2014-01-13 | Method of reducing exercise-induced joint pain in non-arthritic mammals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2846644A1 CA2846644A1 (en) | 2015-07-13 |
| CA2846644C true CA2846644C (en) | 2018-05-01 |
Family
ID=51610711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2846644A Active CA2846644C (en) | 2013-10-24 | 2014-01-13 | Method of reducing exercise-induced joint pain in non-arthritic mammals |
Country Status (14)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10226513B2 (en) | 2015-01-09 | 2019-03-12 | Mark Terrell Smith | Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration |
| WO2018052695A1 (en) * | 2016-09-16 | 2018-03-22 | Boston Scientific Neuromodulation Corporation | System for pain management using heart sounds |
| EP3932298A1 (en) | 2016-09-27 | 2022-01-05 | Boston Scientific Neuromodulation Corporation | System for pain management using objective pain measure |
| US10610688B2 (en) | 2016-09-27 | 2020-04-07 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop pain management |
| US11793217B1 (en) | 2016-10-04 | 2023-10-24 | Lonza Greenwood Llc | Method of manufacture and pasteurization of products containing undenatured collagen |
| US11850324B2 (en) | 2016-10-12 | 2023-12-26 | Advanced Biomatrix, Inc. | Three-dimensional (3-D) printing inks made from natural extracellular matrix molecules |
| WO2018080887A1 (en) | 2016-10-25 | 2018-05-03 | Boston Scientific Neuromodulation Corporation | System for pain management using baroreflex sensitivity |
| EP3568861B1 (en) | 2017-01-11 | 2024-12-11 | Boston Scientific Neuromodulation Corporation | Pain management based on emotional expression measurements |
| US10631777B2 (en) | 2017-01-11 | 2020-04-28 | Boston Scientific Neuromodulation Corporation | Pain management based on functional measurements |
| US10729905B2 (en) | 2017-01-11 | 2020-08-04 | Boston Scientific Neuromodulation Corporation | Pain management based on muscle tension measurements |
| US10631776B2 (en) | 2017-01-11 | 2020-04-28 | Boston Scientific Neuromodulation Corporation | Pain management based on respiration-mediated heart rates |
| US11089997B2 (en) | 2017-01-11 | 2021-08-17 | Boston Scientific Neuromodulation Corporation | Patient-specific calibration of pain quantification |
| WO2018132529A1 (en) | 2017-01-11 | 2018-07-19 | Boston Scientific Neuromodulation Corporation | Pain management based on brain activity monitoring |
| US10960210B2 (en) | 2017-02-10 | 2021-03-30 | Boston Scientific Neuromodulation Corporation | Method and apparatus for pain management with sleep detection |
| CN106713191B (zh) * | 2017-02-28 | 2020-09-08 | 西安电子科技大学 | 一种多级搜索sage方法 |
| CN107048412A (zh) * | 2017-04-26 | 2017-08-18 | 北京盛美诺生物技术有限公司 | 一种含有ⅱ型胶原蛋白的咀嚼型产品 |
| AU2018304079B2 (en) | 2017-07-18 | 2020-12-03 | Boston Scientific Neuromodulation Corporation | Sensor-based pain management systems and methods |
| EP3655018B1 (en) * | 2017-08-21 | 2025-02-26 | Lonza Greenwood LLC | Composition and nutritional supplement made therefrom |
| JP2020532295A (ja) * | 2017-08-31 | 2020-11-12 | ロンザ，エルエルシー | 健康促進組成物およびサプリメントの使用方法 |
| IT201700111939A1 (it) * | 2017-10-05 | 2019-04-05 | Jointherapeutics S R L | Composizione farmaceutica per l’uso nel trattamento di stati infiammatori |
| US20210290736A1 (en) * | 2018-07-16 | 2021-09-23 | Lonza Consumer Health Inc. | Collagen and Cell Matter Supplement and Method for Administering Same |
| WO2021016665A1 (en) * | 2019-07-30 | 2021-02-04 | Atp Institute Pty Ltd | A gummy composition |
| US20220331406A1 (en) * | 2019-09-30 | 2022-10-20 | Lonza Consumer Health Inc. | Cannabinoid Product for Improving Musculoskeletal Health |
| AU2021213722A1 (en) * | 2020-01-29 | 2022-07-28 | Lonza Greenwood Llc | Joint health composition and use thereof in healthy mammals |
| WO2021178291A1 (en) | 2020-03-03 | 2021-09-10 | Lonza Consumer Health Inc. | Undenatured type ii collagen in food and beverage applications and uses thereof |
| US20230104282A1 (en) | 2020-03-24 | 2023-04-06 | Lonza Greenwood Llc | Undenatured Type II Collagen in Animal Food and Treats |
| EP4146251A1 (en) * | 2020-06-12 | 2023-03-15 | Lonza Greenwood LLC | Undenatured type ii collagen as a supplement for improved endurance, lipid metabolism, and oxidative stress |
| EP4181947A1 (en) * | 2020-08-19 | 2023-05-24 | Lonza Consumer Health Inc. | Method for improving inflammation, joint health, joint mobility, and joint comfort in healthy mammals |
| CN115120618B (zh) * | 2021-03-23 | 2024-01-26 | 安徽盛美诺生物技术有限公司 | 具有改善免疫应答作用的软骨提取物、其制备方法及其用途 |
| EP4412637A4 (en) * | 2021-11-12 | 2025-08-27 | Lonza Greenwood Llc | METHOD OF TREATING SKELETAL JOINTS, COMPOSITION AND ASSOCIATED USES |
| KR102771944B1 (ko) * | 2023-09-25 | 2025-02-26 | (주)온오퍼 | 고함량 액티브 성분을 갖는 반려동물용 츄 형태 영양제 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399347A (en) | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| AU2800492A (en) | 1991-11-08 | 1993-06-07 | Gunilla Lofgren Nisser | Partially occluded contact lens for treating visual and/or brain disorder |
| US5529786A (en) | 1994-02-28 | 1996-06-25 | Moore; Eugene R. | Process and product for treatment of rheumatoid arthritis |
| US5645851A (en) | 1994-02-28 | 1997-07-08 | Moore; Eugene R. | Product for alleviating the symptons of arthritis in mammals |
| US5637321A (en) | 1994-02-28 | 1997-06-10 | Moore; Eugene R. | Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals |
| US6162787A (en) * | 1999-04-02 | 2000-12-19 | Immudyne, Inc. | Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions |
| US6372794B1 (en) * | 1999-08-26 | 2002-04-16 | Marcel E. Nimni | Method for alleviating arthritis in mammals |
| US20020086070A1 (en) | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
| US7083820B2 (en) | 2000-09-29 | 2006-08-01 | Schilling Marvin L | Method for producing biologically active products |
| JP2003048850A (ja) | 2001-06-01 | 2003-02-21 | Nippon Meat Packers Inc | 関節傷害治療剤及び機能性食品 |
| US20060062859A1 (en) * | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
| FR2900155B1 (fr) | 2006-04-21 | 2008-06-27 | Diana Naturals Sa | Hydrolisat de cartilage aviaire, procede d'obtention et utilisations |
| US20100215731A1 (en) | 2009-02-20 | 2010-08-26 | Maastricht University | Method for improving cartilage repair and/or preventing cartilage degeneration in a joint |
| US20110218151A1 (en) * | 2010-03-04 | 2011-09-08 | Joar Opheim | Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate |
| CN101822684B (zh) | 2010-05-27 | 2012-08-15 | 江苏江山制药有限公司 | 用于防治骨关节痛的复方组合制剂及其制备方法 |
| US20120294898A1 (en) | 2011-05-19 | 2012-11-22 | Warsaw Orthopedic, Inc. | Injectable dbm for soft tissue repair |
| CN102423487B (zh) | 2011-12-23 | 2014-04-16 | 内蒙古伊利实业集团股份有限公司 | 一种骨关节保健组合物及其应用 |
| CN103203012A (zh) | 2012-01-12 | 2013-07-17 | 深圳市麦金利实业有限公司 | 关节保健品 |
-
2014
- 2014-01-13 MY MYPI2014001885A patent/MY180106A/en unknown
- 2014-01-13 KR KR1020147010693A patent/KR101664290B1/ko active Active
- 2014-01-13 BR BR112014011741A patent/BR112014011741A2/pt not_active Application Discontinuation
- 2014-01-13 CA CA2846644A patent/CA2846644C/en active Active
- 2014-01-13 WO PCT/US2014/011303 patent/WO2015060888A1/en active Application Filing
- 2014-01-13 US US14/153,841 patent/US9066926B2/en active Active
- 2014-01-13 AU AU2014202041A patent/AU2014202041B8/en active Active
- 2014-01-13 SG SG11201403524RA patent/SG11201403524RA/en unknown
- 2014-01-13 MX MX2014002934A patent/MX347669B/es active IP Right Grant
- 2014-01-21 IN IN193DE2014 patent/IN2014DE00193A/en unknown
- 2014-01-29 CO CO14018154A patent/CO7020846A2/es unknown
- 2014-01-30 AR ARP140100320A patent/AR095104A1/es unknown
- 2014-05-15 CL CL2014001281A patent/CL2014001281A1/es unknown
- 2014-06-24 PH PH12014501453A patent/PH12014501453A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014202041B2 (en) | 2019-11-28 |
| BR112014011741A2 (pt) | 2017-05-30 |
| SG11201403524RA (en) | 2015-05-28 |
| AU2014202041B8 (en) | 2020-04-02 |
| PH12014501453B1 (en) | 2015-01-21 |
| CL2014001281A1 (es) | 2015-10-30 |
| KR101664290B1 (ko) | 2016-10-11 |
| CA2846644A1 (en) | 2015-07-13 |
| CO7020846A2 (es) | 2014-08-11 |
| MX347669B (es) | 2017-05-08 |
| WO2015060888A1 (en) | 2015-04-30 |
| MY180106A (en) | 2020-11-23 |
| AU2014202041A1 (en) | 2015-05-14 |
| MX2014002934A (es) | 2015-09-21 |
| IN2014DE00193A (enrdf_load_stackoverflow) | 2015-05-01 |
| US9066926B2 (en) | 2015-06-30 |
| US20150119335A1 (en) | 2015-04-30 |
| KR20150059132A (ko) | 2015-05-29 |
| PH12014501453A1 (en) | 2015-01-21 |
| AR095104A1 (es) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2846644C (en) | Method of reducing exercise-induced joint pain in non-arthritic mammals | |
| Rémond et al. | Understanding the gastrointestinal tract of the elderly to develop dietary solutions that prevent malnutrition | |
| McDougall et al. | Effects of a very low-fat, vegan diet in subjects with rheumatoid arthritis | |
| Faria et al. | Food components and the immune system: from tonic agents to allergens | |
| JP6811170B2 (ja) | 安全な嚥下を促進する嚥下障害者用栄養製品 | |
| JP2014506254A (ja) | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 | |
| JP2019518744A (ja) | 運動障害を治療又は予防するための栄養組成物 | |
| CN101160065A (zh) | 呼吸功能不全的治疗和预防方法 | |
| Poluektov | Sleep and immunity | |
| TW202114543A (zh) | 誘導飽足感之方法 | |
| ES2995086T3 (en) | Gastrointestinal health composition | |
| Rynders et al. | Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial | |
| JP2006077016A (ja) | オメガＧＡ−３脂肪酸を用いたＩｇＡ腎症の治療 | |
| JP6368368B2 (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| Weinstein | The stress effect | |
| Spinks et al. | Clinical assessment of low-dose osteoinductive protein as a stand-alone regimen in self-reported osteoarthritis | |
| Spinks et al. | In vivo osteoinduction: Evaluating 2-beta coxatene as an immunoinductive compound and novel ingredient for joint support | |
| Umborowati et al. | Lactiplantibacillus plantarum IS-10506 Supplementation Improves Clinical Outcome and Immunology Markers in Psoriasis Vulgaris Patients: A Randomized Controlled Trial | |
| US12208073B2 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma | |
| Fernández-Jaén et al. | Pain reduction and tolerance of Type II Undenatured Collagen (UC-II) collagen in patients with knee oste-oarthritis | |
| Mottaghi et al. | Effects of Vitamin D Supplementation on Nonspecific Musculoskeletal Pain, Quality of Life, Self-Related Health and Sexual Satisfaction: A Randomized Control Trial. | |
| JP2024132501A (ja) | フコイダン含有経口組成物 | |
| Green | There's something new in the air | |
| WILSON et al. | Complementary and Alternative Approaches I | |
| Meyerhoff et al. | Common Discomforts of Pregnancy |